These gain-of-function mutations have been identified primarily in IPMN (approximately 65%), subsequently in adenocarcinoma derived from IPMN, and have been reported to not be mutually exclusive with KRAS mutations in pancreatic cancer [56,57]. This evidence concerns the gene KRAS and adenocarcinoma.